Evolus Inc (EOLS)

$12.22 +0.23 (1.92%)
Market Cap 762.41M
Revenue (ttm) 266.27M
Net Income (ttm) -50.42M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -18.94%
Debt to Equity Ratio 22.01
Volume 876,600
Avg Vol 759,750
Day's Range N/A - N/A
Shares Out 63.59M
Stochastic %K 37%
Beta 0.97
Analysts Strong Sell
Price Target $24.83

Latest News on EOLS

Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference

Mar 25, 2025, 8:00 AM EDT - 8 days ago

Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 21, 2025, 4:05 PM EDT - 12 days ago

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus, Inc. (EOLS) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 11:18 PM EST - 4 weeks ago

Evolus, Inc. (EOLS) Q4 2024 Earnings Call Transcript

Evolus posts quarterly profit on strong sales of cosmetic injection

Mar 4, 2025, 4:17 PM EST - 4 weeks ago

Evolus posts quarterly profit on strong sales of cosmetic injection

Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance

Mar 4, 2025, 4:05 PM EST - 4 weeks ago

Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance

Evolus to Participate in Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences

Feb 27, 2025, 8:00 AM EST - 4 weeks ago

Evolus to Participate in Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences

Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit

Feb 20, 2025, 8:00 AM EST - 5 weeks ago

Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit

Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025

Feb 18, 2025, 8:00 AM EST - 6 weeks ago

Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025

US FDA approves Evolus' anti-wrinkle gels

Feb 13, 2025, 1:45 PM EST - 6 weeks ago

US FDA approves Evolus' anti-wrinkle gels

Evolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels

Feb 13, 2025, 1:30 PM EST - 6 weeks ago

Evolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company's Guidance

Jan 21, 2025, 8:00 AM EST - 2 months ago

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company's Guidance

Evolus: Still Bullish, But Business Faces Tricky Challenges In '25

Jan 14, 2025, 2:00 PM EST - 2 months ago

Evolus: Still Bullish, But Business Faces Tricky Challenges In '25

Evolus, Inc. (EOLS) Q3 2024 Earnings Conference Call Transcript

Nov 6, 2024, 7:28 PM EST - 5 months ago

Evolus, Inc. (EOLS) Q3 2024 Earnings Conference Call Transcript

Evolus Reports Third Quarter 2024 Results

Nov 6, 2024, 4:05 PM EST - 5 months ago

Evolus Reports Third Quarter 2024 Results

Evolus to Participate in Stifel 2024 Healthcare Conference

Nov 1, 2024, 8:00 AM EDT - 5 months ago

Evolus to Participate in Stifel 2024 Healthcare Conference

Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation

Oct 31, 2024, 2:02 PM EDT - 5 months ago

Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation

Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers

Oct 29, 2024, 8:00 AM EDT - 5 months ago

Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers

Evolus to Report Third Quarter Financial Results on November 6, 2024

Oct 23, 2024, 8:00 AM EDT - 5 months ago

Evolus to Report Third Quarter Financial Results on November 6, 2024

Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024

Sep 6, 2024, 8:00 AM EDT - 7 months ago

Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024

Evolus, Inc. (EOLS) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 10:22 PM EDT - 8 months ago

Evolus, Inc. (EOLS) Q2 2024 Earnings Call Transcript

Evolus reports first-ever adjusted profit in Q2 fueled by strong sales of Botox rival

Jul 31, 2024, 4:09 PM EDT - 8 months ago

Evolus reports first-ever adjusted profit in Q2 fueled by strong sales of Botox rival

Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance

Jul 31, 2024, 4:05 PM EDT - 8 months ago

Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance

Evolus to Hold Investor Day on September 12, 2024

Jul 31, 2024, 8:00 AM EDT - 8 months ago

Evolus to Hold Investor Day on September 12, 2024

Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in Australia

Jul 30, 2024, 8:00 AM EDT - 8 months ago

Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in Australia

Evolus to Participate in the Canaccord Genuity 44th Annual Growth Conference

Jul 25, 2024, 8:00 AM EDT - 8 months ago

Evolus to Participate in the Canaccord Genuity 44th Annual Growth Conference

Evolus to Report Second Quarter Financial Results on July 31, 2024

Jul 17, 2024, 8:00 AM EDT - 9 months ago

Evolus to Report Second Quarter Financial Results on July 31, 2024

Evolus Announces Appointment of Albert G. White III to Board of Directors

Jul 1, 2024, 8:00 AM EDT - 9 months ago

Evolus Announces Appointment of Albert G. White III to Board of Directors

Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products

Jun 24, 2024, 8:00 AM EDT - 10 months ago

Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products

Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain

Jun 12, 2024, 8:00 AM EDT - 10 months ago

Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain

Evolus: Chiseling Away At The Aesthetic Market

May 22, 2024, 7:00 AM EDT - 11 months ago

Evolus: Chiseling Away At The Aesthetic Market

Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting

May 20, 2024, 8:30 AM EDT - 11 months ago

Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting

Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women's Wear Daily Beauty CEO Summit

May 15, 2024, 8:30 AM EDT - 11 months ago

Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women's Wear Daily Beauty CEO Summit

Evolus' Sandra Beaver Named Orange County Business Journal's Public Company CFO of the Year

May 10, 2024, 9:10 AM EDT - 11 months ago

Evolus' Sandra Beaver Named Orange County Business Journal's Public Company CFO of the Year

Evolus, Inc. (EOLS) Q1 2024 Earnings Call Transcript

May 7, 2024, 11:27 PM EDT - 11 months ago

Evolus, Inc. (EOLS) Q1 2024 Earnings Call Transcript

Evolus Reports First Quarter 2024 Results and Provides Business Update

May 7, 2024, 4:05 PM EDT - 11 months ago

Evolus Reports First Quarter 2024 Results and Provides Business Update

Evolus to Report First Quarter Financial Results on May 7, 2024

Apr 23, 2024, 4:30 PM EDT - 1 year ago

Evolus to Report First Quarter Financial Results on May 7, 2024

Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®

Apr 17, 2024, 4:05 PM EDT - 1 year ago

Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®

Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Mar 26, 2024, 8:00 AM EDT - 1 year ago

Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Evolus: Smooth Progress As Management Targets $700m Aesthetics Franchise Revenues By 2028

Mar 20, 2024, 2:05 PM EDT - 1 year ago

Evolus: Smooth Progress As Management Targets $700m Aesthetics Franchise Revenues By 2028

Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock

Mar 11, 2024, 7:00 AM EDT - 1 year ago

Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock

Evolus, Inc. (EOLS) Q4 2023 Earnings Call Transcript

Mar 7, 2024, 10:40 PM EST - 1 year ago

Evolus, Inc. (EOLS) Q4 2023 Earnings Call Transcript

Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance

Mar 7, 2024, 4:05 PM EST - 1 year ago

Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance

Evolus Announces Results from European Head-to-Head Filler Trial

Mar 1, 2024, 8:30 AM EST - 1 year ago

Evolus Announces Results from European Head-to-Head Filler Trial

Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences

Feb 27, 2024, 8:30 AM EST - 1 year ago

Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences

Evolus to Report Fourth Quarter and Year End 2023 Results and Provide Business Update on March 7, 2024

Feb 22, 2024, 4:30 PM EST - 1 year ago

Evolus to Report Fourth Quarter and Year End 2023 Results and Provide Business Update on March 7, 2024

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue, Achieving Record Results and Exceeding Expectations; Issues 2024 Guidance

Jan 16, 2024, 5:28 PM EST - 1 year ago

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue, Achieving Record Results and Exceeding Expectations; Issues 2024 Guidance

Evolus Announces the Appointment of Nareg Sagherian to Vice President, Head of Global Investor Relations and Corporate Communications

Jan 4, 2024, 4:05 PM EST - 1 year ago

Evolus Announces the Appointment of Nareg Sagherian to Vice President, Head of Global Investor Relations and Corporate Communications

Evolus Enters into Licensing Agreement with Symatese to Exclusively Distribute Next-Generation Dermal Fillers in Europe

Dec 20, 2023, 8:00 AM EST - 1 year ago

Evolus Enters into Licensing Agreement with Symatese to Exclusively Distribute Next-Generation Dermal Fillers in Europe

Evolus, Inc. (EOLS) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 8:45 PM EST - 1 year ago

Evolus, Inc. (EOLS) Q3 2023 Earnings Call Transcript

Evolus Reports Record Third Quarter 2023 Financial Results and Phase II Data for Extra-Strength 40U Formulation of Jeuveau®

Nov 7, 2023, 4:16 PM EST - 1 year ago

Evolus Reports Record Third Quarter 2023 Financial Results and Phase II Data for Extra-Strength 40U Formulation of Jeuveau®